Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of
The
Securities Exchange Act of 1934
Date
of
Report (Date of earliest event reported) October 14, 2005
Advaxis,
Inc.
|
(Exact
name of registrant as specified in its
charter)
|
Colorado
|
00028489
|
84
- 1521955
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
212
Carnegie
Center #206, Princeton, NJ
|
08546
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code (609)
497-7555
|
(Former
name or former address, if changed since last
report.)
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act
(17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act
(17 CFR 240.13e-4(c))
Item
8.01. Other
Events
On
October 10, 2005, the Registrant issued a press release clarifying the fact
that
its product candidate Lovaxin C, upon successful completion of regulatory
compliance and clinical trials, is expected to be available to treat existing
cervical cancer which has occurred or may occur in the large population of
women
already infected with, or exposed to, the Human Papilloma Virus (the viral
cause
of cervical cancer, “HPV”). Lovaxin C is distinguished from the Merck & Co.
(NYSE: MRK) Pharmaceutical product Gardisil,
which
is
a vaccine that recently successfully completed Phase III trails, and is intended
to prevent the occurrence of cervical cancer in women if administered before
they are exposed to certain types of HPV, but cannot help in the treatment
of
women already infected, some of whom are likely to develop cervical cancer.
See
Registrant’s press release attached hereto as Exhibit 99.1.
Item
9.01. Financial
Statements and Exhibits
a) Not
applicable.
b) Not
applicable.
c) Exhibits
99.1. |
Press
Release, dated October 10, 2005
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
ADVAXIS,
INC. |
|
|
|
Date: October
14, 2005 |
By: |
/s/ J.
Todd Derbin |
|
Name: J.
Todd Derbin |
|
Title:
President and Chief Executive
Officer |